SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-276870
Filing Date
2022-11-03
Accepted
2022-11-03 16:06:22
Documents
14
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d407133d8k.htm   iXBRL 8-K 26738
2 EX-99.1 d407133dex991.htm EX-99.1 87240
6 GRAPHIC g407133g1103095611827.jpg GRAPHIC 8600
  Complete submission text file 0001193125-22-276870.txt   260357

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eigr-20221103.xsd EX-101.SCH 2861
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20221103_lab.xml EX-101.LAB 18759
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20221103_pre.xml EX-101.PRE 11714
8 EXTRACTED XBRL INSTANCE DOCUMENT d407133d8k_htm.xml XML 3480
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 221357934
SIC: 2836 Biological Products, (No Diagnostic Substances)